Toralgen is developing a proprietary polybile nanopill delivery technology that has many unique properties to deliver active drug compounds to targeted sites in the body. Our platform has the potential to present therapeutics to patients in a preferred and convenient dosage formIt also provides the opportunity to improve patient adherence and move a drug earlier in the treatment algorithm by offering an oral form. The company is currently exploring potential therapies for diabetes and autoimmune disorders but may expand into cancer research in the future.
In 2019, 37.3 million Americans had diabetes1. About 1.45 million of them have the autoimmune disease Type 1 diabetes2 and there are more than 24 million people in the United States affected by one or more of the 80 autoimmune diseases3. That’s the potential impact even before we address cancer.
Our patented nanotechnology allows orally delivered medications to transit the stomach unaltered allowing for absorption in the intestine with distribution to key organs including the liver, spleen, pancreas, small intestines, and lymphatic organs. In the low pH environment of the stomach, our nanoparticles lock away their cargo resulting in an often undetectable release of the drug. At neutral pH, such as in blood, our nanoparticles open to release drug at a much faster rate. This natural physical property of the poly bile nanoparticle allows for delivery of drug classes from small molecules to peptides to monoclonal antibodies.
For discovery we employ single and double emulsion sonication techniques to iterate quickly toward a set of conditions we can transfer to a scalable manufacturing processes such as microfluidics. At Toralgen, we operate a microfluidics system at the pilot scale for semicontinuous manufacturing and processing. Downstream processing is through tangential flow filtration (TFF) and lyopholization. These processes allow single batch production in a scalable manner and improved encapsulation and formulation consistency.